A cheap arthritis drug shows promise treating RSV in early study
An arthritis drug has shown potential in reducing RSV in human respiratory cells according to an early study. While the findings are promising, experts caution that laboratory results may not translate to real-world effectiveness. Further research is needed before considering the drug for clinical use in treating RSV infections.
- ▪The arthritis drug indomethacin significantly reduces RSV in laboratory studies.
- ▪RSV is a major cause of hospitalization for infants and poses risks to older adults.
- ▪Experts emphasize that laboratory findings do not guarantee real-world effectiveness.
Opening excerpt (first ~120 words) tap to expand
Health Medicine & Drugs A cheap arthritis drug shows promise treating RSV in early study An arthritis drug reduces the amount of RSV in human respiratory cells, but experts say it's too early to say if it will actually treat the common infection. By Clarissa Brincat published 3 June 2026 in News When you purchase through links on our site, we may earn an affiliate commission. Here’s how it works. Respiratory syncytial virus, or RSV, is a common respiratory infection that poses serious risks to certain groups, including young children and older adults.
…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Live Science.
Discussion
0 commentsMore from Live Science
